Incidence and treatment of hemophagocytic lymphohistiocytosis in hospitalized children with Ehrlichia infection

Stephanie S. Cabler, Patrick G. Hogan, Stephanie A. Fritz, Jeffrey Bednarski, David Hunstad

Research output: Contribution to journalArticle

Abstract

We report a large cohort of pediatric patients with human monocytic ehrlichiosis (HME), enabling an estimated incidence of secondary hemophagocytic lymphohistiocytosis (HLH) in hospitalized children with HME. Among 49 children with PCR-confirmed Ehrlichia infection, 8 (16%) met current criteria for HLH. Those with HLH had more significant hematologic abnormalities and longer durations from symptom onset to admission and definitive anti-infective therapy. Among these eight, three received chemotherapy plus doxycycline, one of whom died; the other five were treated with doxycycline without chemotherapy, and all survived without HLH recurrence. Our findings demonstrate that antimicrobial therapy alone can successfully resolve Ehrlichia-associated HLH.

Original languageEnglish
JournalPediatric Blood and Cancer
DOIs
StateAccepted/In press - 2020

Keywords

  • doxycycline
  • Ehrlichia
  • hemophagocytic lymphohistiocytosis
  • hyperferritinemia

Fingerprint Dive into the research topics of 'Incidence and treatment of hemophagocytic lymphohistiocytosis in hospitalized children with Ehrlichia infection'. Together they form a unique fingerprint.

  • Cite this